Telephone: 612-625-8999; FAX: 612-625-5620
Hot-topic debate on kidney function: Renal-sparing approaches are ineffective†
Article first published online: 26 OCT 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Supplement: Liver Transplant Immunosuppression: “Does One Size Fit All?”
Volume 17, Issue Supplement S3, pages S50–S53, November 2011
How to Cite
Lake, J. R. (2011), Hot-topic debate on kidney function: Renal-sparing approaches are ineffective. Liver Transpl, 17: S50–S53. doi: 10.1002/lt.22429
Potential conflict of interest: Nothing to report.
- Issue published online: 26 OCT 2011
- Article first published online: 26 OCT 2011
- Accepted manuscript online: 24 AUG 2011 01:55PM EST
- Manuscript Received: 19 AUG 2011
- Manuscript Accepted: 19 AUG 2011
- 12Preserving renal function in liver transplantation. Efficacy and safety of a mycophenolate mofetil (MMF)/sirolimus maintenance regimen following calcineurin inhibitor (CNI) withdrawal: interim data from the Spare-the-Nephron (STN) trial [abstract]. Hepatology 2007; 46( suppl 1): 269A, , , , , , et al.
- 13Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II study. Liver Transpl 2011; 17( suppl 1): S79., , , , , , et al.
- 15Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11: 1064-1072., , , , , , et al.